Spero Therapeutics Inc Cash Flow-to-Debt Ratio
Spero Therapeutics Inc cash flow-to-debt ratio. Spero Therapeutics Inc (SPRO) has a Cash Flow-to-Debt Ratio of -0.84x as of December 2025, meaning its operating cash flow of $-8.35 Million could theoretically repay -1% of its total liabilities ($9.90 Million) in one year. Check SPRO cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Spero Therapeutics Inc (2015–2025)
Cash flow-to-debt ratio of Spero Therapeutics Inc from 2015 to 2025. Historical debt coverage capacity for Spero Therapeutics Inc across 11 annual periods. Check cash flow reinvestment rate of Spero Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
Spero Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
Spero Therapeutics Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Spero Therapeutics Inc. For the full cash flow conversion analysis, see Spero Therapeutics Inc cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.28x | $-12.62 Million | $9.90 Million | ▼ -250.5% |
| 2024 | -0.36x | $-23.44 Million | $64.42 Million | ▲ +16.7% |
| 2023 | -0.44x | $-32.99 Million | $75.50 Million | ▼ -176.3% |
| 2022 | -0.16x | $-7.73 Million | $48.87 Million | ▲ +79.6% |
| 2021 | -0.78x | $-64.35 Million | $82.78 Million | ▲ +80.6% |
| 2020 | -4.01x | $-85.87 Million | $21.41 Million | ▼ -152.8% |
| 2019 | -1.59x | $-50.02 Million | $31.53 Million | ▲ +47.3% |
| 2018 | -3.01x | $-39.62 Million | $13.15 Million | ▲ +34.3% |
| 2017 | -4.59x | $-39.11 Million | $8.52 Million | ▼ -17.4% |
| 2016 | -3.91x | $-28.96 Million | $7.41 Million | ▼ -202.3% |
| 2015 | -1.29x | $-9.61 Million | $7.43 Million | — |